CTMX · CytomX Therapeutics Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 2.18 USD |
|---|---|
| 1-day change | -2.2% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 27 / 17 / 26 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 6 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +10.0% |
| Sales growth Q/Q | -88.9% |
| Distance from 52-week high | +67.7% |
| Market cap (USD) | $962.0M |